FDA updates PAH label with trial data - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

  • By

  • Kathryn Wighton

  • September 22, 2026

  • 3 min

Share

Original Source(s)

FDA updates PAH label with trial data

  • by Kathryn Wighton

  • September 22, 2026

Related Content

Acupuncture for Neuroinfections?

A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.

Tele-guided lung ultrasound may be acceptable to paramedics

Trainees rated remote-guided imaging favorably, while technical reliability and communication emerged as barriers to implementation.

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.